Remove ads

Indivior Finals

Lemon Quarter
Posts: 1378
Joined: November 4th, 2016, 11:20 am
Has thanked: 58 times
Been thanked: 338 times

Indivior Finals


Postby tjh290633 » February 22nd, 2017, 7:10 pm ... 00094858X/

The market seemed disappointed. Maybe because of:

The Company recorded a charge of $220m in the third quarter of 2016 for the investigative and antitrust litigation matters disclosed under Litigation Update on pages 8-9. The Company continues in discussions with the Department of Justice about a possible resolution to its investigation. The Company cannot predict with any certainty whether it will be able to reach ultimate resolution with the Department of Justice or any or all of the other parties, or the ultimate cost of resolving all of the matters. The final cost may be materially higher than this reserve.

As announced before, no dividends for now.

In the full year, the Group repaid $78m (2015: $112m) of its term loan as part of its commitment under the syndicated debt facility. The final dividend for 2015 was $69m, paid in July 2016 (2015: interim dividend of $23m). The Board has determined that it does not expect to pay further dividends in the foreseeable future.

The initial shareholders resolved, by a special resolution, passed on October 30, 2014, to reduce Indivior PLC's share capital by decreasing the nominal value of each Indivior Ordinary Share from $2.00 to $0.10. This created distributable reserves on the balance sheet that will provide Indivior with, among other things, capacity for the payment of future dividends.

Until now they have had a good run up in the price. Will it continue? If not, maybe time to exit.


Return to “Pharmaceuticals”

Who is online

Users browsing this forum: No registered users and 1 guest